RBSH (Rebus Hldgs) ROE % Adjusted to Book Value: Negative Equity% (As of Jun. 2023)


What is Rebus Hldgs ROE % Adjusted to Book Value?

Rebus Hldgs RBSH ROE % Adjusted to Book Value is Negative Equity% as of Jun. 2023.

Rebus Hldgs's ROE % for the quarter that ended in Jun. 2023 was Negative Equity. Rebus Hldgs's PB Ratio for the quarter that ended in Jun. 2023 was N/A. Rebus Hldgs's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 was Negative Equity.

Rebus Hldgs ROE % Adjusted to Book Value Related Terms

Rebus Hldgs ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Rebus Hldgs's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rebus Hldgs ROE % Adjusted to Book Value Chart

Rebus Hldgs Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 Negative Equity 0.00

Rebus Hldgs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 Negative Equity Negative Equity 0.00 Negative Equity

RBSH vs KRBP, CNBX, EVFM: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Rebus Hldgs's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rebus Hldgs ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rebus Hldgs's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Rebus Hldgs's ROE % Adjusted to Book Value falls into.


Rebus Hldgs ROE % Adjusted to Book Value Calculation

Rebus Hldgs's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Rebus Hldgs's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=Negative Equity / N/A
=Negative Equity

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of Negative Equity% mean?
Rebus Hldgs (RBSH) has a ROE % Adjusted to Book Value of Negative Equity% as of Jun. 2023. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Rebus Hldgs and its competitors.
Is Rebus Hldgs' ROE % Adjusted to Book Value too high?
Rebus Hldgs' current ROE % Adjusted to Book Value is Negative Equity%.
How does Rebus Hldgs' ROE % Adjusted to Book Value compare to KRBP and CNBX?
Rebus Hldgs' ROE % Adjusted to Book Value of Negative Equity% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Rebus Hldgs and its competitors. Rebus Hldgs's current ROE % Adjusted to Book Value is Negative Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rebus Hldgs stock overvalued right now?
Rebus Hldgs (RBSH) has a current ROE % Adjusted to Book Value of Negative Equity%. The current ROE % Adjusted to Book Value is Negative Equity%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Rebus Hldgs (RBSH), the current ROE % Adjusted to Book Value is Negative Equity% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rebus Hldgs Business Description

Address 2629 Townsgate Road, Suite 215, Westlake Village, CA, USA, 91361
Rebus Hldgs Inc is an early-stage, pre-revenue, pharmaceutical company that is focused on the development of prodrug cancer therapeutics for the treatment of disease. The company along with its subsidiaries is engaged in the production of small-molecule adenosine receptor modulators. Adenosine is an extracellular signaling molecule that regulates multiple aspects of tissue function and specifically plays a role in immunity and inflammation.